Data investigation

Five Clicks Instead of a Quarter Milligram

One in five people on the label's titration schedule quit because of gut side effects. On a slower schedule it was one in fifty, at the same final dose, with the same results.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·1 citation

One in five people in the standard-titration arm of this trial quit because of gastrointestinal side effects. In the arm that climbed more slowly, it was one in fifty, and both groups ended on similar doses with similar blood sugar and weight results.[1] If that holds up, the schedule printed on the label is costing a substantial number of people their treatment for nothing.

What the two schedules were

One hundred and four people with type 2 diabetes were randomized to one of two semaglutide schedules over 26 weeks. The label’s schedule steps up every four weeks, from 0.25 mg to 0.5 mg to 1 mg. The other was slower and flexible.

The flexible arm started at 0.0675 mg, which the paper describes as five clicks of the pen’s dose selector dial. That is roughly a quarter of the label’s already-low starting dose. From there it rose by another 0.0675 mg each week, with increases postponed whenever gastrointestinal side effects appeared.

Results at 26 weeks.[1]
Flexible titrationLabel titrationP
Withdrew due to GI side effects2%19%0.005
Reported nausea45.1%64.2%0.051
Days with nausea2.886.30.017
Asthenia (weakness)9.8%24.5%0.047
Final doseSimilarSimilar—
HbA1c and BMI changeSimilarSimilar—

Read the nausea row honestly

The headline difference in nausea did not reach statistical significance. At P = 0.051 it sits a thousandth on the wrong side of the conventional line. It is going to be quoted as though it did, and it should not be. What did reach significance is the number of days people spent nauseated, the rate of weakness and, most important, how many people gave up.

That combination is coherent even with the nausea rate itself unresolved. Roughly similar proportions may feel sick, but for fewer days, less severely, and with the option of pausing the climb. That is the difference between an unpleasant few months and quitting.

Same destination, gentler road, and about a ninth as many people quitting over side effects.

Why this matters more than most trial results

Almost everything in this field trades benefit against harm: more weight loss, more side effects. This does not. The flexible arm reached comparable doses and comparable results. The cost of the gentler schedule was time, and the return was a large reduction in people abandoning treatment.

Discontinuation is the central problem with these drugs. People stop, and weight comes back; that is the whole subject of what happens when you stop. Anything that keeps people on treatment without costing efficacy is worth more than another percentage point of weight loss.

It also reframes what the label’s starting dose is for. The 0.25 mg step exists to be tolerated rather than to work, and this trial suggests that for a substantial minority it is not low enough to do that job.

Why this is not a set of instructions

Counting clicks on a pen dial is not a validated way to measure a dose. These devices are engineered to deliver the marked increments, not fractions between them, and the accuracy of a five-click dose is not something a manufacturer certifies. In the trial, that was done inside a protocol with clinicians supervising and a schedule to follow.

The thing to take from it is not a number of clicks but that slowing down is a legitimate option with randomized evidence behind it. A prescriber can hold a dose or extend the interval, and the labels already contain language for that: “as tolerated.” Someone struggling with the standard climb has something specific to bring to that conversation now.

The same click-counting technique used as a permanent low dose rather than a slow start is a different practice with a different evidence base, covered in microdosing. Some sellers now sell low-dose compounded semaglutide as a plan of its own, and our semaglutide microdose board lists them with what each one charges.

The limits

  • It is a pilot. One hundred and four people, described as such by the authors.
  • Open-label. Everyone knew which schedule they were on, and expectation affects reported nausea more than most outcomes.
  • Type 2 diabetes only, on semaglutide doses up to 1 mg, not the 2.4 mg used for weight management, where the climb is longer and the top dose higher.
  • Twenty-six weeks, which covers the titration period and little beyond it.
  • The paper carries a published erratum whose content we have not read.

Frequently Asked Questions

In this randomized pilot, 2% of the slow-titration group withdrew because of gastrointestinal side effects against 19% on the label schedule, with fewer days of nausea and less weakness. Final doses, HbA1c and BMI were similar.
No. Both arms ended on similar doses with similar changes in blood sugar and body weight. The cost of the gentler schedule was time.
0.0675 mg, measured as five clicks of the pen's dose selector dial, or roughly a quarter of the label's lowest step. It was done inside a supervised trial protocol, and counting clicks is not a manufacturer-validated way to measure a dose.
Not by the conventional threshold. Nausea was reported by 45.1% against 64.2%, at P = 0.051. What did reach significance was the number of days spent nauseated, the rate of weakness, and how many people withdrew.
That conversation is exactly what this evidence supports. The labels already build 'as tolerated' language into their titration schedules so a clinician can hold a dose or extend an interval. There is now randomized evidence that doing so keeps people on treatment.

References

  1. 1.Eldor R, Avraham N, Rosenberg O, et al. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen Diabetes Care. 2025. PMID: 40673973.

Not Taking It and Not Tolerating It

Real-world studies usually measure adherence and stopping separately, with every kind of stopping counted the same way. That merges someone whose body cannot tolerate the drug with someone not taking it reliably. A Scottish study separated them and found different predictors.

6 min read

Every Other Week: Stretching the Interval

Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.

5 min read

A Pill to Hold What the Injection Lost

Daily oral orforglipron maintained 79.3% of weight already lost against 37.6% on placebo at a year in people coming off semaglutide, and 74.7% against 49.2% after tirzepatide. The trial had no arm that stayed on the injection, which is the question people actually have.

5 min read

What Tripling the Dose Buys

A higher semaglutide dose produced 18.7% weight loss against 15.6% on the standard dose. Three extra percentage points is the benefit; the costs are in the safety table.

7 min read

The Top Dose Keeps Not Being Worth It

Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.

7 min read

Stopping Ozempic or Wegovy: Side Effects, Weight Regain and Keeping It Off

Stopping Ozempic or Wegovy causes no withdrawal syndrome on either label. Appetite returns as semaglutide clears over about five weeks, and a 2026 BMJ meta-analysis found regain of about 0.8 kg a month. What helps keep weight off, and what women should know.

10 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

7.3

Found

People who want clinician visits billed to commercial insurance, with compounded medication in the plan price

From $149/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →